stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Return on equity
Denali Therapeutics Inc.'s return on equity over the twelve months to 30 September 2026 was −33.9%, up 11.8 percentage points from fiscal 2025 (−45.7%). Over the past ten years it has ranged from −47.5% (fiscal 2017) to 157.9% (fiscal 2016); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −45.7% | (8.29) |
| FY2024 | −37.4% | (23.39) |
| FY2023 | −14.0% | 18.51 |
| FY2022 | −32.5% | (5.01) |
| FY2021 | −27.5% | (36.72) |
| FY2020 | 9.21% | 51.18 |
| FY2019 | −42.0% | (34.81) |
| FY2018 | −7.16% | 40.30 |
| FY2017 | −47.5% | (205.31) |
| FY2016 | 157.9% | 127.27 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| DNLI Denali Therapeutics Inc. | −33.9% |
| IDYA IDEAYA Biosciences, Inc. compare | −38.5% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement